BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7324177)

  • 1. VM 26 in advanced mycosis fungoides.
    Tirelli U; Carbone A; Tumolo S; Galligioni E; Veronesi A; Trovò MG; Grigoletto E
    Tumori; 1981 Oct; 67(5):487-90. PubMed ID: 7324177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas.
    Sorio R; Tirelli U; Zagonel V; Carbone A; Monfardini S
    Am J Clin Oncol; 1990 Feb; 13(1):14-6. PubMed ID: 2305716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
    Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
    Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: Chemotherapy of mycosis fungoides.
    Jacobs P; King HS; Gordon W
    S Afr Med J; 1975 Jul; 49(32):1286. PubMed ID: 1154194
    [No Abstract]   [Full Text] [Related]  

  • 5. Epipodophyllotoxin (VP-16-213) in mycosis fungoides: A report from the Scandinavian mycosis fungoides study group.
    Molin L; Thomsen K; Volden G; Bergqvist-Karlsson A; Hallberg O; Hellbe L
    Acta Derm Venereol; 1979; 59(1):84-7. PubMed ID: 84480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of teniposide in advanced breast cancer.
    Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
    Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adriamycin therapy in advanced mycosis fungoides.
    Levi JA; Diggs CH; Wiernik PH
    Cancer; 1977 May; 39(5):1967-70. PubMed ID: 858126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of VM 26 in extensively pretreated breast cancer.
    Tirelli U; Franchin G; Crivellari D; Veronesi A; Galligioni E; Trovó MG; Talamini R; Tumolo S; Grigoletto E
    Am J Clin Oncol; 1984 Oct; 7(5):451-2. PubMed ID: 6507365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photochemotherapy (PUVA) in the tumour stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group.
    Molin L; Thomsen K; Volden G; Groth O
    Acta Derm Venereol; 1981; 61(1):52-4. PubMed ID: 6164215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
    Cox EB; Vogel CL; Carpenter JT; Raney M
    Invest New Drugs; 1988 Apr; 6(1):37-9. PubMed ID: 3410666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged remission of tumor-stage mycosis fungoides by topical immunotherpay.
    Vonderheid EC; Dellatorre DL; Van Scott EJ
    Arch Dermatol; 1981 Sep; 117(9):586-9. PubMed ID: 6457569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VM-26 in colorectal carcinoma: a Southwest Oncology Group study.
    Oishi N; Fleming TR; Laufman L; Ungerleider JS; Natale RB; Einstein AB; Von Hoff DD; Macdonald JS
    Invest New Drugs; 1990 Feb; 8(1):93-5. PubMed ID: 2188930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prednimustine in mycosis fungoides: a report from the Scandinavian mycosis fungoides study group.
    Molin L; Thomsen K; Volden G; Bergqvist-Karlsson A; Hellbe L
    Acta Derm Venereol; 1979; 59(1):87-8. PubMed ID: 84481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread.
    Roupe G; Sandström MH; Kjellström C
    Acta Derm Venereol; 1996 Nov; 76(6):475-8. PubMed ID: 8982416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of teniposide (VM-26) in multiple myeloma.
    Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
    Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma.
    Kuzel TM; Hurria A; Samuelson E; Tallman MS; Roenigk HH; Rademaker AW; Rosen ST
    Blood; 1996 Feb; 87(3):906-11. PubMed ID: 8562961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
    van der Burg ME; ten Bokkel Huinink WW; Vriesendorp R; van Oosterom AT; Neijt JP; Vermorken JB; van Putten WL; Kooiman A
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):997-8. PubMed ID: 3666002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
    Janiga J; Kentley J; Nabhan C; Abdulla F
    Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose teniposide for refractory malignancies: a phase I study.
    de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
    Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012.
    Dummer R; Quaglino P; Becker JC; Hasan B; Karrasch M; Whittaker S; Morris S; Weichenthal M; Stadler R; Bagot M; Cozzio A; Bernengo MG; Knobler R
    J Clin Oncol; 2012 Nov; 30(33):4091-7. PubMed ID: 23045580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.